{{cart_num}}
My CartCAS：2482-00-0
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：White to off-white Solid
Qty：
Size：
| CAS | 2482-00-0 |
| Name | Agmatine Sulfate |
| Molecular Formula | C5H14N4·H2SO4 |
| Molecular Weight | 228.27 |
| Solubility | Soluble in Water ≥5mg/mL |
| Purity | ≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 219-617-3 |
| MDL | MFCD00013109 |
| SMILES | NC(NCCCCN)=N.O=S(O)(O)=O |
| Target Point | Imidazoline Receptor，NO Synthase |
| Passage | GPCR & G Protein;Neuronal Signaling |
| Background | Agmatine Sulfate plays a regulatory role on multiple targets, such as neurotransmitter system, ion channel, nitric oxide synthesis. It is an endogenous agonist and NO synthase inhibitor of imidazoline receptor. |
| Biological Activity | Agmatine sulfate在多个靶点上发挥调节作用，如神经递质系统，离子通道，一氧化氮合成。它是 imidazoline receptor 的内源性激动剂和 NO synthase 抑制剂。[1-7] |
| In Vitro | 胍丁胺与α2-肾上腺素能和咪唑啉受体结合，并刺激肾上腺嗜铬细胞释放儿茶酚胺。其生物合成酶精氨酸脱羧酶存在于脑中。局部合成的胍丁胺是咪唑啉受体的内源性激动剂，是α2-肾上腺素能受体的非儿茶酚胺配体，可作为神经递质[1]。胍丁胺在大脑中合成，储存在区域选择性神经元的突触小泡中，通过摄取积累，通过去极化释放，并通过农杆菌酶灭活。胍丁胺抑制一氧化氮合酶，并诱导一些肽激素的释放[2]。胍丁胺4-(氨基丁基)胍是通过酶精氨酸脱羧酶使L-精氨酸脱羧而产生的。胍丁胺是所有NOS同工酶的竞争性抑制剂，但不是NO前体。 Ki值约为660μM(NOS I)，220μM(NOS II)和7.5 mM(NOS III)[3]。胍丁胺刺激亚硝酸盐产生比内皮细胞形成的基础亚硝酸盐高三倍。胍丁胺从内皮细胞膜中置换[3H] - 脱氮嗪，并且发现其诱导内皮细胞的胞质钙中的瞬变。通过反复接触胍丁胺可以下调瞬变，但不受去甲肾上腺素预处理的影响[4]。 |
| In Vivo | 当在强迫游泳测试和小鼠尾部悬浮试验(剂量范围0.01-50mg / kg，ip)中评估时，胍丁胺产生类似抗抑郁药的效果，而没有伴随开放场中移动的变化[5]。在缺血性中风中，胍丁胺可以保护血脑屏障，可以通过使用动态对比增强磁共振成像定量渗透性来体内监测[6]。胍丁胺大大增强了MK-801的抗抑郁样作用，强化了这种化合物调节NMDA受体激活的观点[7]。 |
| Animal Experiment | 大鼠：将34只雄性Sprague-Dawley大鼠进行瞬时MCA闭塞90分钟。再灌注后，立即将胍丁胺(100mg / kg)或生理盐水腹膜内注射到胍丁胺处理组(n = 17)或对照组。再灌注后进行MR成像[6]。小鼠：用一系列亚有效剂量的氟西汀(1，2.5和5 mg / kg，po;选择性5-羟色胺再摄取抑制剂)，丙咪嗪(0.01，0.05和0.1 mg / kg，po;三环)预处理小鼠。抗抑郁药)，安非他酮(0.1，0.5和1 mg / kg，po;对去甲肾上腺素能再摄取具有微妙活性的多巴胺再摄取抑制剂)，或MK-801(0.0001，0.0005和0.001 mg / kg，po;非竞争性NMDA受体拮抗剂)并立即之后，给予亚有效剂量的胍丁胺(0.0001mg / kg口服)或赋形剂。 60分钟后，对动物进行行为测试[7]。 |
| Data Literature Source | [1]. Li G，et al. Agmatine: an endogenous clonidine-displacing substance in the brain. Science. 1994 Feb 18;263(5149):966-9. [2]. Reis DJ，et al. Is agmatine a novel neurotransmitter in brain Trends Pharmacol Sci. 2000 May;21(5):187-93. [3]. Galea E，et al. Inhibition of mammalian nitric oxide synthases by agmatine，an endogenouspolyamine formed by decarboxylation of arginine. Biochem J. 1996 May 15;316 ( Pt 1):247-9. [4]. Morrissey JJ，et al. Agmatine activation of nitric oxide synthase in endothelial cells. Proc Assoc Am Physicians. 1997 Jan;109(1):51-7. [5]. Zomkowski AD，et al. Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport. 2002 Mar 25;13(4):387-91. [6]. Ahn SS，et al. Effects of agmatine on blood-brain barrier stabilization assessed by permeability MRI in a rat model of transient cerebral ischemia. AJNR Am J Neuroradiol. 2015 Feb;36(2):283-8. [7]. Neis VB，et al. Agmatine enhances antidepressant potency of MK-801 and conventional antidepressants in mice. Pharmacol Biochem Behav. 2015 Mar;130:9-14 |
| Unit | Bottle |
| Specification | 100mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Manual Download
